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Abstract
Background: Measurement of thyroglobulin (Tg) protein in the washout of the needle used for fine needle
aspiration biopsy cytology (FNAB-C) has been shown to increase the sensitivity of FNAB-C in identifying cervical
lymph node (CLN) metastasis from well-differentiated thyroid cancer (TC). In this study, we evaluated whether
routine measurement of Tg protein (FNAB-Tgp), Tg mRNA (FNAB-Tgm) and calcitonin (CT) mRNA (FNAB-CTm) in
the FNAB washout of CLN increases the accuracy of FNAB-C in the diagnosis of suspicious metastatic CLN.
Methods: In this prospective study 35 CLN from 28 patients were examined. Histology showed metastatic papillary
TC (PTC) in 26 CLN, metastatic medullary TC (MTC) in 3 CLN, metastatic anaplastic TC (ATC) in 3 CLN and 3
metastatic CLN from extra-thyroidal cancers.
Results: The overall accuracy of FNAB-C was 84.4%, reaching 95.7% when the analysis was restricted to PTC. Both
FNAB-Tgp and FNAB-Tgm compared favorably with FNAB-C and shown diagnostic performances not statistically
different from that of FNAB-C. However, FNAB-Tgp and FNAB-Tgm/FNAB-CTm were found useful in cases in which
cytology results were inadequate or provided diagnosis inconsistent with patient's clinical parameters.
Conclusions: We demonstrated that FNAB-C, Tg/CT mRNA and Tg protein determination in the fine-needle
washout showed similar accuracy in the diagnosis of metastatic CLN from TC. The results of this study suggest that
samples for Tg protein and Tg/CT mRNA measurements from CLN suspicious for metastatic TC should be collected,
but their measurements should be restricted to cases in which FNAB-C provides uninformative or inconsistent
diagnosis with respect to patient's clinical parameters.
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Background
Thyroid cancer represents the most frequent endocrine
neoplasia, accounting for 1.7% (0.7% in male and 2.7% in
female) of all new malignant diseases and 0.5% (0.3% in
male and 0.7% in female) of deaths related to cancer
worldwide [1,2]. Thyroid carcinomas originate mostly
from the epithelial follicular cells and are represented
for 95% by the differentiated (DTC) papillary (PTC) and
follicular (FTC) carcinomas, while 1-2% of them are the
undifferentiated and unvaryingly fatal anaplastic carcin-
omas (ATC) [3]. The remaining 3-4% are medullary thy-
roid carcinomas (MTC) derived from the parafollicular
C cells [4]. The accurate diagnosis of locoregional lymph
node metastasis is of primary importance for the initial
surgical approach as well as for prognostic stratification
and follow-up [4-9]. In this context, fine-needle aspir-
ation biopsy cytology (FNAB-C) represents the gold
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standard technique for the detection of cervical lymph
node (CLN) metastasis [4-9]. The latter, however, relies
on the experience and ability of the cytopathologist, and
may be a challenging diagnostic category as CLN could
harbor metastasis from a multiplicity of extrathyroidal
malignancies or be affected by several non-tumoral diseases
[9-11]. In addition, inadequate cellularity or nonrepre-
sentative sampling, often associated with cystic lymph
nodes, prevents diagnosis in about 20% of specimens
[12-14]. Over the last two decades, a number of studies
have demonstrated that measurement of thyroglobulin
protein (Tgp) in the washout of the needle used for
FNAB (FNAB-Tgp) increases the sensitivity of FNAB-C
in identifying CLN metastasis from DTC [14-27]. As a
consequence, routine association of FNAB-Tgp with
FNAB-C in the diagnosis of CLN metastasis from
papillary and follicular thyroid cancers has been re-
commended [6,7,15]. Similarly, it has been shown that
lymph node detection of Tg mRNA (Tgm) in fine-
needle washout implemented the FNAB-C sensitivity
for the diagnosis of metastatic CLN from DTC, even if this
still needs to be validated on larger case-studies [28].
In the present work we evaluated, in 35 consecutive
CLN for which the histological diagnosis was available,
if routine measurement of thyroglobulin (Tg) protein
and Tg and calcitonin (CT) mRNA in the washout of
the needle used for FNAB increases the sensitivity of
FNAB-C in identifying cervical lymph node (CLN) me-
tastasis from either DTC or MTC. The results obtained
suggest that while samples for Tg protein and Tg/CT
mRNA measurements from CLN suspicious for meta-
static thyroid cancer should be always collected, their
measurements should be restricted to cases in which
FNAB-C gives uninformative or inconsistent diagnosis
with respect to patient’s biochemical and/or clinical
parameters.
Methods
Patients
The case study included 35 cervical lymph nodes (CLN)
with definitive diagnosis from 28 consecutive patients
referred, from September 2004 to October 2012, to the
outpatients’ clinic of Endocrinology and Thyroid Diseases
of the Policlinico Umberto I general hospital of Rome
(Italy). The study was approved by the ethical committee
of the Policlinico Umberto I hospital in agreement to
the declaration of Helsinki and all patients gave written
informed consent. Patients, 7 males and 21 females with
a median age of 39.5 yr (range 20-72 yr), with single or
multiple suspicious CLN underwent fine-needle aspir-
ation biopsy (FNAB) followed by cytological (FNAB-C)
evaluation, Tgp measurement, and Tgm and CTm as-
sessment in the fine needle washout. Among them, 9
patients previously underwent total thyroidectomy with
histological diagnosis of papillary thyroid cancer (see
Table 1). All patients with thyroid cancer underwent
unilateral neck dissection. The histological diagnosis
showed metastatic PTC in 21 patients, metastatic MTC
in 2, metastatic ATC in 2 and metastasis from extra-
thyroidal cancers in the remaining 3 patients (1 non-
Hodgkin lymphoma, 1 rhino-pharyngeal and 1 lung
carcinoma). The enlarged lymph nodes from the latter
3 patients were evaluated since they all presented thy-
roid nodules with ultrasound features suspicious of
malignancy (i.e. hypoechogenicity, presence of irregular
margins and microcalcifications).
Ultrasonography, fine-needle aspiration biopsy (FNAB)
and fine-needle washout
Thyroid ultrasonography (US) was performed on the
cervical area using the Aplio XV (Toshiba, Japan) system
equipped with a linear transducer (PLT-805AT). The
scanning was performed on patients’ neck hyper-
extended in supine position. US parameters suggestive
of malignant lymph node infiltration included: rounded
shape and long-to-short axis ratio inferior to 1.5; ir-
regular echogenicity; presence of microcalcifications;
irregular vascularity, i.e. peripheral or mixed (hilar and
peripheral) vascularity. Following US, patients selected
for the FNAB were instructed not to take aspirin or
any other anticoagulant in the 5 days prior to biopsy.
A 25 -gauge needle, attached to 20 ml plastic syringe,
was used to aspirate nodes under US assistance. Two
to three separate aspiration from each CLN were made.
All aspirates were smeared directly on glass slides for cyto-
logical examination as described below. The needle was
then washed with 1 ml of phosphate buffered saline (PBS)
by multiple pumping actions and the suspension was
centrifuged at 1200 rpm for 5 min. The supernatant was
collected and frozen to -20°C until analyzed for Tg protein
level (FNAB-Tgp), while the pellet was quickly frozen in
liquid nitrogen and stored at -80°C.
Cytological and histological analysis
Following FNAB the needle’s material was expelled onto
glass slides and smeared with a second slide to spread
the material across the surface. The slides were then
either air-dried or wet-fixed using the Bio-Fix (Bio-
Optica, Milan, Italy). Air-dried slides were stained with
a May Grunwald-Giemsa solution, while the wet-fixed
slides were stained with the Papanicolaou solution. For
the histological diagnosis, soon after lymphadenectomy
the tissue was placed in 10% buffered formalin and
paraffin embedded. Four μm thick sections were then
prepared and stained with hematoxylin and eosin [29].
Both cytological and histological diagnoses were made
by two expert pathologists and were concordant in all cases.
Both pathologists were, at the time of their diagnoses,
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unaware of Tgp, Tgm and CTm results as well the molecu-
lar biologists were unaware, at the time of their diagnoses,
of the patologists diagnoses.
Tg protein and Tg autoantibody measurements
Tgp levels in the FNAB washout were measured using the
immunoluminometric assay (ILMA) Tg-PluS (B.R.A.H.M.S.,
Hennigsdorf, Germany). The analytical and functional
sensitivity of the assay was, respectively, 0.02 ng/ml and
0.15 ng/ml. Tg values below the functional sensitivity were
considered undetectable [30]. Samples were assayed in
duplicate either non-diluted or following 1:10, 1:100
and 1:1000 dilutions in PBS. Results were expressed as
ng/FNAB [19]. Even if FNAB-Tgp measurement has
Table 1 Cytological, molecular and histological diagnoses of suspicious metastatic cervical lymph nodes (CLN) from
thyroid cancer patients
CLN number FNAB-C FNAB-Tgp (ng/FNAB) FNAB-Tgm FNAB-CTm Histology
1 IN 6620 + - Met. PTC
2 IN 7480 + - Met. PTC
3 Met. PTC 5652 + - Met. PTC
4* Met. PTC 5293 + - Met. PTC
5* Met. PTC 18612 + - Met. PTC
6 Met. PTC 1625 + - Met. PTC
7 Met. MTC 0.9 - + Met. MTC
8* IN 37.50 IN IN Met. PTC
9 Met. PTC 26108 + - Met. PTC
10 Met. ATC UND + - Met. ATC
11 Met. PTC 37250 ND ND Met. PTC
12 Met. PTC 0.8 + - Met. ATC
13 Met. PTC 2.82 - - Met. ATC
14* Met. PTC 114 + - Met. PTC
15* Met. PTC 288 - - Met. PTC
16 Met. PTC 1151 + - Met. PTC
17 Met. PTC 3714 + - Met. PTC
18 Met. PTC 480 + - Met. PTC
19 Met. PTC UND - + Met. MTC
20 Met. PTC UND - + Met. MTC
21* Met. PTC 62908 IN IN Met. PTC
22 Met. PTC 72.3 + - Met. PTC
23 Met. PTC 10349 + - Met. PTC
24 Met. PTC 384 ND ND Met. PTC
25* Met. PTC 728 ND ND Met. PTC
26 Met. PTC 53 + - Met. PTC
27 Met. PTC ND + - Met. PTC
28* Met. PTC ND + - Met. PTC
29* Met. PTC ND + - Met. PTC
30 Epithelial CA UND - - Met. RFC
31 Lymphoma 10.9 - - Lymphoma
32 Met. LC UND - - Met. LC
33 Met. PTC 3361 + - Met. PTC
34* Benign 4395 - - Met. PTC
35* Met. PTC 4388 + - Met. PTC
FNAB-C, fine-needle aspiration biopsy (FNAB) cytology; FNAB-Tgp, FNAB thyroglobulin protein; FNAB-Tgm, FNAB Tg mRNA; FNAB-CTm, FNAB CT mRNA; ND, non-
determined; UND, undetectable; IN, inadequate; Pos. WBS, positive whole body scan; RFC, rhino-pharyngeal carcinoma; CA, cancer; LC, lung cancer. * CLN from
previously thyroidectomized patients.
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been reported to be non-affected by serum Tg autoanti-
bodies [31], all FNAB washout samples were routinely
assayed for Tg autoantibodies using the Anti-Tgn kit from
B.R.A.H.M.S. with a functional sensitivity of 20 U/ml.
In all samples Tg autoantibodies were undetectable
(below 20 U/ml).
Extraction and analysis of RNA
The above mentioned pellets have been resuspended in
500 μl of Isol-RNA lysis reagent (Eppendorf, Milano,
Italy) and total RNA extracted as previously described
[32]. In particular, the precipitation of RNA has been
maximized by adding 20 μg of molecular biology-grade
glycogen to isopropanol. The RNA has been reverse-
transcribed using anchored Oligo(dT)23 primers and
M-MLV reverse transcriptase (Sigma Aldrich Co. St-Louis,
MO). Negative controls have been performed in parallel
for all samples omitting the reverse transcriptase in the
RT reaction mix. PCR mix has been prepared with dNTPs
0.2 mM, 1.5 U of HotMaster Taq DNA Polymerase
(Eppendorf, Milano, Italy), 5 μl of 10x Taq buffer containing
Mg2+, specific Tg, CT and beta-2-microglobulin (B2M)
primers 0.5 μM, 2-3 μl of cDNA, and molecular biology-
grade water to 50 μl. In particular, the sequences of the
above primers were as follows: Tg, forward CTCTGGAAA
GATTCTGACATGG (exon 28-29), reverse CTCTGGAA
AGATTCTGACATGG (exon 30-31) (amplicon 243 bp);
CT, forward CCTTCCTGGCTCTCAGCATC (exon 2), re-
verse GAGTTTAGTTGGCATTCTGG (exon 4) (amplicon
407); B2M, forward CAGCAGAGAATGGAAAGTC (exon
2), reverse CATGCTGCTTACATGTCTCG (exon 3)
(amplicon 269 bp). After 2 min of initial denaturation at
94°C, 40 cycles have been run as follows: 94°C for
20 sec, 56-60°C for 10 sec, 65°C for 50 sec. Positive con-
trols, represented by normal human thyroid tissue for
Tg mRNA and the MTC derived cell line TT for CT
mRNA, have been included each time. The obtained
amplicons have been visualized by agarose gel electro-
phoresis, and their specificities have been checked by
automated DNA sequencing (Primm, Milano, Italy).
Statistical analysis
Sensitivity, specificity, diagnostic accuracy, positive and
negative predictive value of each diagnostic test were
calculated. Differences in sensitivity, specificity, negative
and positive predictive values and accuracy among the
different tests were evaluated by the Fisher exact test.
Cohen’s k coefficient was used to estimate the agreement
between various diagnostic tests. Statistical calculations
were performed using Stata version 8.0 (College Station,
Texas, Stata Corporation, 2003). The results were con-
sidered statistically significant when the two-tailed p
value was <0.05.
Results
FNAB cytology (FNAB-C) versus histological diagnosis
As reported in Table 1, FNAB-C was inadequate in 3
(8.6%) out the 35 samples of CLN, 2 of which were from
anaechoic (cystic) CLN and 1 from hypoechoic CLN.
The FNAB-C diagnosis of the 32 CLN was correctly pro-
vided in 27 cases, with accuracy of 84.4%. In the
remaining 5 cases FNAB-C diagnosis of metastatic PTC
in 4 CLN was incorrect because the histology demonstrated
2 metastatic MTC (Table 1, CLN n. 19 and 20) and 2 meta-
static ATC (Table 1, CLN n. 12 and 13), while the fifth
CLN with a benign cytology turned out to be a metastatic
PTC (Table 1, CLN n. 34) These 5 FNAB-C diagnoses were
considered as false negative. The specificity, sensitivity,
positive (PPV) and negative (NPV) predictive values and
accuracy of FNAB-C are reported in Table 2.
FNAB Tg protein (FNAB-Tgp) versus histological diagnosis
As reported in Figure 1 and Table 1, Tgp level in the
fine-needle washout was measured in 32 out of the 35
CLN with definitive diagnosis. In order to limit false
negative results considered unacceptable and in agree-
ment with other studies, we decided to adopt a Tgp
cut-off value of 1 ng/FNAB [16]. FNAB-Tgp provided
correct diagnoses in 29 CLN (24 true positive and 5 true
negative), false negative results (Tgp level <1 ng/FNAB)
in 2 harboring metastatic ATC and false positive result
in one with definitive diagnosis of lymphoma. Among
the 23 CLN in which histology showed metastatic PTC,
Tgp values ranged from 37.5 ng to 62908 ng (mean
8742 ng/FNAB; SD 15001 ng). In Table 2, specificity,
sensitivity, PPV, NPV and accuracy of FNAB-Tgp are
reported.
FNAB Tg (FNAB-Tgm) and CT (FNAB-CTm) mRNA versus
histological diagnosis
Tg and CT mRNA levels were measured in 32 out of the
35 CLN with definitive diagnosis. In 2 cases samples
were judged inadequate because of the absence of β2-
microglobulin mRNA. As shown in Tables 1 and 2, the
analysis of Tg mRNA in the fine-needle washout of
the 30 samples provided a correct diagnosis in 27 cases
(21 true positive and 6 true negative CLN) and 3 false
negative results, 1 with definitive diagnosis of metastatic
ATC and 2 of metastatic PTC.
The CT mRNA analysis provided correct results in all
30 samples (3 true positive and 27 true negative).
Comparison of the different tests in the diagnosis of
suspicious CLN
The comparison of the diagnostic parameters of FNAB-
C, FNAB-Tgp and FNAB-Tgm, alone or in combination,
was performed excluding from the case series 3 CLN
harboring metastasis from MTC and 3 CLN affected by
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extrathyroidal cancers. Specificity, sensitivity, PPV, NPV
and accuracy are reported in Table 3.
As it may be noticed, the diagnostic performances
were comparable and not significantly different among
FNAB-Tgp, FNAB-Tgm and FNAB-C. In addition, the
combined use of FNAB-Tgp + FNAB-Tgm or FNAB-C +
FNAB-Tgp + FNAB-Tgm did not improve significantly
the diagnostic value of FNAB-C alone (Table 3).
When the analysis was restricted to the 26 CLN harbor-
ing metastatic PTC FNAB-C and FNAB-Tgp showed, re-
spectively, 95.7 and 100% accuracy and, in the 20 CLN in
which both diagnoses were available, a 95% overall agree-
ment between the 2 tests was observed (Table 3). On the
other hand, FNAB-Tgm showed 90.5% accuracy and an
overall agreement of 94.7% (Cohen’s k = 0.64, p < 0.01)
with FNAB-C in the 19 CLN in which both diagnoses
were attained.
Regarding the 3 CLN harboring metastatic ATC (Table 1,
CLN number 10, 12 and 13), FNAB-C identified correctly
one of them (CLN number 10) and gave the erroneous
diagnosis of metastatic PTC in the remaining two (from
the same patient). As expected, in these 3 CLN FNAB-Tgp
levels were low, only one (Table 1, CLN number 13) being
above the cut-off value. On the other hand, FNAB-Tgm
was positive in two CLN (Table 1, CLN number 10 and 12)
and negative in one.
FNAB-Tgp provided a correct diagnosis in all 3 CLN
with uninformative cytology. Also FNAB-Tgm provided
correct diagnosis in 2 of the 3 CLN with inadequate cy-
tology, being inadequate as well as in the third case.
Discussion
Cytological evaluation of FNAB represents the gold
standard technique for the diagnosis of CLN suspected
to harbor metastatic disease from thyroid cancer as well
as from other primary tumors. The technique accuracy,
highly dependent on the experience and ability of the cy-
topathologist, has been reported to vary from 73% to
94% [17,18,22,25]. Over the last years, following clinical
evidence showing that FNAB-Tgp in fine-needle washout
improves the accuracy of FNAB-C in the evaluation of
CLN metastases of DTC, it has been recommended the
routine association of FNAB-Tgp with FNAB-C in the
preoperative diagnosis of suspicious CLN [6,7,14-27,33].
We here report our experience with 35 CLN for which
a definitive diagnosis was available, including cases har-
boring metastases from PTC, MTC, ATC and other
primary tumors.
The results showed that, on 32 CLN harboring metas-
tases from papillary and anaplastic thyroid carcinomas,
FNAB-C had 88.5% accuracy, that is within the range
reported in other studies [17,18,22,25]. When FNAB-Tgp
and FNAB-Tgm were used singly they had a diagnostic
performance comparable and not statistically different
from that of FNAB-C. In addition, the combination of
FNAB-Tgp and/or FNAB-Tgm with FNAB-C did not
improve significantly the diagnostic value of FNAB-C.
On the other hand, both FNAB-Tgp and FNAB-Tgm
compared favorably with FNAB-C. As expected, a major
disagreement among the three diagnostic tests was ob-
served in the 3 CLN harboring metastasis from ATC
(Table 2, CLN number 10, 12 and 13). It is worth to
note that although ATC are undifferentiated cancers,
i.e. devoid of thyroid specific gene expression, we consider
Table 2 Diagnostic performance of different tests for diagnosis of suspicious metastatic cervical lymph nodes (CLN)
from thyroid cancer patients (n = 35)
Test Sensitivity Specificity PPV NPV Accuracy
FNAB-C 84.4 (27/32) [67.2-94.7] N.D. (0/0) [N.D.] 100 (27/27) [87.2-100] N.D. (0/5) [0-52.2] 84.4 (27/32) [67.2-94.7]
FNAB-Tgp 92.3 (24/26) [74.9-99.1] 83.3 (5/6) [35.9-99.6] 96.0 (24/25) [79.7-99.9] 71.4 (5/7) [29.0-96.3] 90.6 (29/32) [77.7-103.5]
FNAB-Tgm 87.5 (21/24) [67.6-97.3] 100 (6/6) [54.1-100] 100 (21/21) [83.9-100] 66.7 (6/9) [29.9-92.5] 90.0 (27/30) [76.3-103.7]
FNAB-CTm 100 (3/3) [29.2-100] 100 (27/27) [87.2-100] 100 (3/3) [29.2-100] 100 (27/27) [87.2-100] 100 (30/30) [100-100]
PPV, positive predictive value; NPV, negative predictive value; C, cytology; Tgp, thyroglobulin protein; Tgm, thyroglobulin mRNA; CTm, calcitonin mRNA. N.D., non-
determined. In round brackets the number of cases. In square brackets the 95% confidence interval.
Figure 1 Thyroglobulin concentrations in fine-needle biopsies
of 32 cervical lymph nodes with histological diagnosis. MTC,
medullary thyroid cancer (n = 3); NTC, non-thyroidal cancers (n = 3);
TC, epithelial thyroid cancer (n = 26); PTC, papillary thyroid cancer
(n = 23); ATC, anaplastic thyroid cancer (n = 3).
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the absence or the low level (below the cut-off value of
1 ng/FNAB) of Tgp or the absence of Tgm as false nega-
tive results. In fact, in one of the three metastatic CLN
from ATC the detectable Tgp correctly diagnosed one of
them (CLN number 13), and the detectable Tgm was diag-
nostic in the other two (CLN number 10 and 12).
A major diagnostic value of FNAB-Tgp and FNAB-
Tgm was observed in cases of uninformative FNAB-C,
given that in all 3 CLN characterized by inadequate cy-
tology FNAB-Tgp provided the correct diagnosis. In
these cases, FNAB-Tgm also provided the correct diag-
nosis in 2 of them, being inadequate in one. Other in-
stances in which the combined use of FNAB-Tgp,
FNAB-Tgm and FNAB-CTm is valuable include those
cases in which FNAB-C diagnosis is not consistent with
patient’s clinical and biochemical parameters. This was
the case (Table 1, CLN number 19 and 20) of the patient
harboring metastatic MTC and characterized by elevated
level of serum calcitonin in which FNAB-C indicated
metastatic PTC, while on the contrary both FNAB-Tgp
and FNAB-Tgm were negative, and FNAB-CTm positive.
Conclusions
FNAB-C remains the gold standard technique for the
diagnosis of suspicious CLN due to its ability to efficiently
diagnose metastasis not only from thyroid cancers, but
also from other primary tumors. If confirmed on larger
case studies, the results of this study suggest that samples
Table 3 Diagnostic performance of the different tests employed in the diagnosis of suspicious metastatic cervical
lymph nodes (CLN) from thyroid cancer patients
Test Sensitivity Specificity PPV NPV Accuracy
PTC + ATC CLN (n = 29)
FNAB-C 88.5 (23/26) [69.9-97.6] N.D. (0/0) [N.D.] 100 (23/23) [85.2-100] N.D. (0/3) [0-70.8] 88.5 (23/26) [69.9-97.6]
FNAB-Tgp 92.3 (24/26) [74.9-99.1] N.D. (0/0) [N.D.] 100 (24/24) [85.8-100] N.D. (0/2) [0-84.2] 92.3 (24/26) [74.9-99.1]
FNAB-Tgm 87.5 (21/24) [88.1-100] N.D. (0/0) [N.D.] 100 (21/21) [84.0-100] N.D. (0/3) [0-70.8] 87.5 (21/24) [88.1-100]
FNAB-Tgp + -Tgm 100 (29/29) [88.1-100] N.D. (0/0) [N.D.] 100 (29/29) [88.1-100] N.D. (0/0) [N.D.] 100 (29/29) [88.1-100]
FNAB-C + -Tgp 96.6 (28/29) [82.2-99.9] N.D. (0/0) [N.D.] 100 (28/28) [87.7-100] N.D. (0/1) [0-97.5] 96.6 (28/29) [82.2-99.9]
FNAB-C + -Tgm 92.9 (26/28) [76.5-99.1] N.D. (0/0) [N.D.] 100 (26/26) [86.8-100] N.D. (0/2) [0-84.2] 92.9 (26/28) [76.5-99.1]
FNAB-C + -Tgp + -Tgm 100 (29/29) [88.1-100] N.D. (0/0) [N.D.] 100 (29/29) [88.1-100] N.D. (0/0) [N.D.] 100 (29/29) [88.1-100]
Only PTC CLN (n = 26)
FNAB-C 95.7 (22/23) [78.1-99.9] N.D. (0/0) [N.D.] 100 (22/22) [84.6-100] N.D. (0/1) [0-97.5] 95.7 (22/23) [78.1-99.9]
FNAB-Tgp 100 (23/23) [85.2-100] N.D. (0/0) [N.D.] 100 (23/23) [85.2-100] N.D. (0/0) [N.D.] 100 (23/23) [85.2-100]
FNAB-Tgm 90.5 (19/21) [69.6-98.8] N.D. (0/0) [N.D.] 100 (19/19) [82.4-100] N.D. (0/2) [0-84.2] 90.5 (19/21) [69.6-98.8]
Upper panel includes 26 CLN with metastatic PTC and ATC. Lower panel includes 23 CLN with only metastatic PTC. PPV, positive predictive value; NPV, negative
predictive value; C, cytology; Tgp, thyroglobulin protein; Tgm, thyroglobulin mRNA. In bracket the number of cases. N.D., non-determined.
Figure 2 Flow-chart for diagnosis of suspicious metastatic cervical lymph nodes (CLN) from thyroid cancer patients. Following fine-
needle aspiration biopsies (FNAB) samples for Tg protein and Tg/CT mRNA measurements should be collected but their analysis restricted to
cases with uninformative or clinically unsound FNAB-C diagnosis. Tg, thyroglobulin; CT, calcitonin.
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for Tg/CT mRNA and Tg protein measurements from
CLN suspicious for metastatic thyroid cancer should be
always collected (Figure 2), but their measurements
should be restricted to cases in which FNAB-C give un-
informative or inconsistent diagnosis with respect to pa-
tient’s biochemical and/or clinical parameters. Finally, it
is also worth to mention that this approach may signifi-
cantly reduce the costs of the management of patients
with thyroid cancer whose incidence has been increas-
ing over the last years, being actually the fifth most
common cancer in women.
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